Multiple Sclerosis Clinical Trials in Phoenix

Showing 241-260 of 490 trials

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

NCT01970410

MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for PML. This is a two center interventional study of patients who have had 12 or more continuous infusions of natalizumab , who are anti-JCV-ab positive, and who had been free of clinical relapses during prior 12 months of natalizumab therapy who will be switching to teriflunomide. SUB-STUDY: To study the number of patients experiencing a reduction in the anti-JCV antibody Index value in patients who had received at least one dose of teriflunomide during participation in the SWITCH protocol (main study).

Multiple Sclerosis

Providence Health & Services55 participantsStarted Oct 2013

Phoenix, Arizona, United States • Latham, New York, United States • Portland, Oregon, United States

COMPLETEDPhase 1/2< 1 mile

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

NCT02657889

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)

NeoplasmsTriple Negative Breast CancerOvarian Cancer+6 more

Tesaro, Inc.122 participantsStarted Apr 2016

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +27 more locations

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Multiple Sclerosis Trials in Other Cities

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

PEN-866 in Patients With Advanced Solid Malignancies

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

An Extension of the TG1101-RMS201 Trial

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

Natural History of Optic Neuritis

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Other Conditions in Phoenix